Clinical Trials Logo

Filter by:
NCT ID: NCT05581979 Active, not recruiting - Clinical trials for Salivary Gland Tumor

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers

Start date: January 26, 2022
Phase:
Study type: Observational

The objectives of this pilot feasibility study, which is on the use of 68-Ga PSMA PET imaging of salivary gland tumours, are - to determine the proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer; and - to determine if in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. The hypotheses of this study are that there is high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers; and that in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging.

NCT ID: NCT05581550 Recruiting - Clinical trials for Nasopharyngeal Cancer

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Start date: June 29, 2020
Phase: N/A
Study type: Interventional

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

NCT ID: NCT05579912 Completed - Anastomotic Leak Clinical Trials

The Diagnostic Dilemma of Anastomotic Leak in Esophagogastric Surgery

Start date: November 28, 2019
Phase:
Study type: Observational

To study the diagnostic specificity and sensitivity of various modalities used for the assessment of anastomotic leak in esophagogastric surgery and to identify the most sensitive technique. Secondarily, to propose a clinical algorithm to guide clinicians in the diagnosis of anastomotic leaks esophagogastric surgeries.

NCT ID: NCT05579262 Completed - Clinical trials for Dietary Nitrate Supplementation

Evaluating the Metabolic Effects of Dietary Nitrate Supplementation

NIMMI
Start date: July 8, 2022
Phase: N/A
Study type: Interventional

Dietary nitrate is found to enhance muscle fatty acid oxidation/glucose uptake and increase mitochondrial biogenesis, which in turn, aid in the prevention and management of metabolic diseases. In recent years, inorganic nitrate supplementation is clinically emerging as a therapeutic strategy for possible treatment and management of metabolic diseases and cardiometabolic disorders. This is mostly explored in healthy/obese subjects, for improving blood pressure, endothelial function, insulin response and vascular effects. However, the metabolic effects of dietary nitrate for improving skeletal muscle glucose/lipid metabolism, muscle mitochondrial metabolism, muscle blood flow and body fat composition are not comprehensively studied in diabetic/pre-diabetic subjects. Hence, this study aims to evaluate the therapeutic efficacy of a natural nitrate supplement (beetroot juice) for improving overall metabolic health in obese pre-diabetic and non-diabetic subjects.

NCT ID: NCT05575882 Recruiting - Atopic Dermatitis Clinical Trials

Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin.

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).

NCT ID: NCT05574270 Recruiting - Cataract Clinical Trials

Clinical Investigation of a Small Aperture Extended Depth of Focus Intraocular Lens in Patients With Complex Corneas

Start date: July 12, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the clinical outcomes of the IC-8 IOL implanted in patients with complex corneas after crystalline lens removal.

NCT ID: NCT05573230 Completed - Healthy Clinical Trials

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Start date: October 17, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.

NCT ID: NCT05572866 Completed - COVID-19 Clinical Trials

Impact of COVID-19 Pandemic on Hepatopancreatobiliary Surgical Services in Singapore

Start date: January 1, 2019
Phase:
Study type: Observational

This paper is intended to report our observational study in evaluating the impact of the COVID-19 pandemic on Tan Tock Seng Hospital hepatopancreatobiliary unit's surgical workload from January to June across 2019 to 2022, corresponding to the pre-pandemic baseline to its peak and the gradual normalization of hospital services as Singapore entered the transition phase to COVID-19 resilience.

NCT ID: NCT05569304 Not yet recruiting - Obesity Clinical Trials

Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study

EGG
Start date: October 7, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to compare the 1-year total body weight loss outcomes for Class 1 and Class 2 Obesity patients who have undergone endoscopic sleeve gastroplasty (ESG) in contrast to medical treatment with glucagon-like peptide-1 (GLP-1) analogues.

NCT ID: NCT05568953 Recruiting - Infectious Disease Clinical Trials

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

We hypothesize that a high CD4+ and CD8+ T cell count will reduce viremia upon challenge with a structurally heterologous virus, and correspondingly result in reduced magnitude of host response to challenge infection. Primary Objective: To compare, after challenge with a structurally heterologous vaccine, the differences in levels of viremia between healthy adults who received primary vaccination with either YF17D vaccine, chimeric JE-YF17D vaccine, or inactivated JE vaccine. 58 subjects will be randomised into 1 of 2 arms (Arm B1 and Arm B2) in a 1:1 ratio, in a double-blind fashion. Subjects in Arm B1 will receive JE-YF17D vaccine (Imojev, Sanofi Pasteur) on Day 0 followed by YF17D vaccine (Stamaril, Sanofi Pasteur) on Day 28. Subjects in Arm B2 will receive Stamaril on Day 0 followed by Imojev on Day 28. Arm B3 will be conducted as a separate single-arm open label design in 14 subjects. Subjects in Arm B3 will receive inactivated JE vaccine (Ixiaro, Valneva) on Day 0 followed by Stamaril on Day 28. The rationale for these three study arms is as follows: Arm B1 will show the impact low levels of viremia, and the resultant low levels of virus-specific CD4+ and CD8+ T cells, would have on YF17D infection. In contrast, YF17D vaccination in Arm B2 would produce high levels of viremia, and in turn high levels virus-specific T cells, thus likely ameliorating JE-YF17D infection. Arm B3 will serve as the control arm, as vaccination with inactivated JE vaccine would not produce any YF17D-specific T cell response. Notably, the first vaccination in Arms B1 and B2 would also provide the viremia response in the absence of virus-specific T cells, which would serve as a reference point to interpret the outcome of the second vaccination.